Investigating the tension between cloud-related actors and individual privacy rights

Historically, little more than lip service has been paid to the rights of individuals to act to preserve their own privacy. Personal information is frequently exploited for commercial gain, often without the person’s knowledge or permission. New legislation, such as the EU General Data Protection Regulation Act, has acknowledged the need for legislative protection. This Act places the onus on service providers to preserve the confidentiality of their users’ and customers’ personal information, on pain of punitive fines for lapses. It accords special privileges to users, such as the right to be forgotten. This regulation has global jurisdiction covering the rights of any EU resident, worldwide. Assuring this legislated privacy protection presents a serious challenge, which is exacerbated in the cloud environment. A considerable number of actors are stakeholders in cloud ecosystems. Each has their own agenda and these are not necessarily well aligned. Cloud service providers, especially those offering social media services, are interested in growing their businesses and maximising revenue. There is a strong incentive for them to capitalise on their users’ personal information and usage information. Privacy is often the first victim. Here, we examine the tensions between the various cloud actors and propose a framework that could be used to ensure that privacy is preserved and respected in cloud systems

An assessment of blockchain consensus protocols for the Internet of Things

In a few short years the Internet of Things has become an intrinsic part of everyday life, with connected devices included in products created for homes, cars and even medical equipment. But its rapid growth has created several security problems, with respect to the transmission and storage of vast amounts of customers data, across an insecure heterogeneous collection of networks. The Internet of Things is therefore creating a unique set of risk and problems that will affect most households. From breaches in confidentiality, which could allow users to be snooped on, through to failures in integrity, which could lead to consumer data being compromised; devices are presenting many security challenges to which consumers are ill equipped to protect themselves from. Moreover, when this is coupled with the heterogeneous nature of the industry, and the interoperable and scalability problems it becomes apparent that the Internet of Things has created an increased attack surface from which security vulnerabilities may be easily exploited. However, it has been conjectured that blockchain may provide a solution to the Internet of Things security and scalability problems. Because of blockchain’s immutability, integrity and scalability, it is possible that its architecture could be used for the storage and transfer of Internet of Things data. Within this paper a cross section of blockchain consensus protocols have been assessed against a requirement framework, to establish each consensus protocols strengths and weaknesses with respect to their potential implementation in an Internet of Things blockchain environment

The George Eliot Archive: Current Reception & Comparison of DH Projects 2020

• Current legal gray area for digital collections: An exception for public libraries and archives as educational tools exists for copyright infringement, but digital archives are not currently protected by this exception unless they can prove that the content is transformative. • Benefits of archiving scholarship together: Grouping like scholarship together regardless of genre or authorship allows for unique cross-purpose or interdisciplinary connections to be drawn from the collection. • Humanists of today must devote time and resources to the educational tools and platforms of tomorrow: Without the successful building and completion of means to ensure digital archives can be maintained throughout the future, all work will be done in vain

A secure and scalable IoT consensus protocol

Several consensus algorithms have been proposed as a way of resolving the Byzantine General problem with respect to blockchain consensus process. However, when these consensus algorithms are applied to a distributed, asynchronous network some suffer with security and/or scalability issues, while others suffer with liveness and/or safety issues. This is because the majority of research have not considered the importance of liveness and safety, with respect to the integrity of the consensus decision. In this paper a novel solution to this challenge is presented. A solution that protects blockchain transactions from fraudulent or erroneous mis-spends. This consensus protocol uses a combination of probabilistic randomness, an isomorphic balance authentication, error detection and synchronised time restrictions, when assessing the authenticity and validity of IoT request. Designed to operate in a distributed asynchronous network, this approach increases scalability while maintaining a high transactional throughput, even when faced with Byzantine failure

The development and implementation of an oxygen treatment solution for health facilities in low and middle-income countries

Background Oxygen reduces mortality from severe pneumonia and is a vital part of case management, but achieving reliable access to oxygen is challenging in low and middle-income country (LMIC) settings. We developed and field tested two oxygen supply solutions suitable for the realities of LMIC health facilities. Methods A Health Needs Assessment identified a technology gap preventing reliable oxygen supplies in Gambian hospitals. We used simultaneous engineering to develop two solutions: a Mains-Power Storage (Mains-PS) system consisting of an oxygen concentrator and batteries connected to mains power, and a Solar-Power Storage (Solar-PS) system (with batteries charged by photovoltaic panels) and evaluated them in health facilities in The Gambia and Fiji to assess reliability, usability and costs. Results The Mains-PS system delivered the specified ≥85% (±3%) oxygen concentration in 100% of 1-2 weekly measurements over 12 months, which was available to 100% of hypoxaemic patients, and 100% of users rated ease-of-use as at least ‘good’ (90% very good or excellent). The Solar-PS system delivered ≥85% ± 3%) oxygen concentration in 100% of 1-2 weekly measurements, was available to 100% of patients needing oxygen, and 100% of users rated ease-of-use at least very good. Costs for the systems (in US dollars) were: PS$9519, Solar-PS standard version$20 718. The of oxygen for a standardised 30-bed health facility using 1.7 million litres of oxygen per year was: for cylinders 3.2 cents (c)/L in The Gambia and 6.8 c/L in Fiji, for the PS system 1.2 c/L in both countries, and for the Solar-PS system 1.5 c/L in both countries. Conclusions The oxygen systems developed and tested delivered high-quality, reliable, cost-efficient oxygen in LMIC contexts, and were easy to operate. Reliable oxygen supplies are achievable in LMIC health facilities like those in The Gambia and Fiji

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Background Neutrophil serine proteases are involved in the pathogenesis of COVID-19 and increased serine protease activity has been reported in severe and fatal infection. We investigated whether brensocatib, an inhibitor of dipeptidyl peptidase-1 (DPP-1; an enzyme responsible for the activation of neutrophil serine proteases), would improve outcomes in patients hospitalised with COVID-19. Methods In a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial, across 14 hospitals in the UK, patients aged 16 years and older who were hospitalised with COVID-19 and had at least one risk factor for severe disease were randomly assigned 1:1, within 96 h of hospital admission, to once-daily brensocatib 25 mg or placebo orally for 28 days. Patients were randomly assigned via a central web-based randomisation system (TruST). Randomisation was stratified by site and age (65 years or ≥65 years), and within each stratum, blocks were of random sizes of two, four, or six patients. Participants in both groups continued to receive other therapies required to manage their condition. Participants, study staff, and investigators were masked to the study assignment. The primary outcome was the 7-point WHO ordinal scale for clinical status at day 29 after random assignment. The intention-to-treat population included all patients who were randomly assigned and met the enrolment criteria. The safety population included all participants who received at least one dose of study medication. This study was registered with the ISRCTN registry, ISRCTN30564012. Findings Between June 5, 2020, and Jan 25, 2021, 406 patients were randomly assigned to brensocatib or placebo; 192 (47·3%) to the brensocatib group and 214 (52·7%) to the placebo group. Two participants were excluded after being randomly assigned in the brensocatib group (214 patients included in the placebo group and 190 included in the brensocatib group in the intention-to-treat population). Primary outcome data was unavailable for six patients (three in the brensocatib group and three in the placebo group). Patients in the brensocatib group had worse clinical status at day 29 after being randomly assigned than those in the placebo group (adjusted odds ratio 0·72 [95% CI 0·57–0·92]). Prespecified subgroup analyses of the primary outcome supported the primary results. 185 participants reported at least one adverse event; 99 (46%) in the placebo group and 86 (45%) in the brensocatib group. The most common adverse events were gastrointestinal disorders and infections. One death in the placebo group was judged as possibly related to study drug. Interpretation Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with COVID-19

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

The George Eliot Archive: Current Reception & Comparison of DH Projects 2020

• Current legal gray area for digital collections: An exception for public libraries and archives as educational tools exists for copyright infringement, but digital archives are not currently protected by this exception unless they can prove that the content is transformative. • Benefits of archiving scholarship together: Grouping like scholarship together regardless of genre or authorship allows for unique cross-purpose or interdisciplinary connections to be drawn from the collection. • Humanists of today must devote time and resources to the educational tools and platforms of tomorrow: Without the successful building and completion of means to ensure digital archives can be maintained throughout the future, all work will be done in vain

Data for: To ascertain if blockchain can facilitate the internet of things security and scalability requirements

ABSTRACT Several consensus algorithms have been proposed as a way of resolving the Byzantine General problem with respect to blockchain consensus process. However, when these consensus algorithms are applied to a distributed, asynchronous network some suffer with security and/or scalability issues, while others suffer with liveness and/or safety issues. This is because the majority of research have not considered the importance of liveness and safety, with respect to the integrity of the consensus decision. In this paper a novel solution to this challenge is presented. A solution that protects blockchain transactions from fraudulent or erroneous mis-spends and mistakes. This consensus protocol uses a combination of probabilistic randomness, an isomorphic balance authentication, error detection and synchronised time restrictions, when assessing the authenticity and validity of IoT request. Designed to operate in a distributed asynchronous network, this approach increases scalability while maintaining a high transactional throughput, even when faced with Byzantine failure